Hard Tissue, Thin Evidence: Recovery & Tissue Repair Research Peptides Under Review

The short version

Saints Peptides is a reading desk. It is not a shop, not a clinic, and it sells nothing. It covers four research peptides that come up constantly whenever people talk about healing the hard parts of the body — bone, cartilage, joint surfaces and the places where tendon meets bone. They are BPC-157, TB-500, GHK-Cu and KLOW, a blend of four peptides supplied in one vial.

One fact shapes everything below it. Nearly all of the encouraging research on these peptides was done in rats, mice, dogs, cells in a dish, or — in one case — the membrane inside a chicken egg. Animal results are a reason to keep studying a compound. They are not evidence that the same thing happens in a person.

A second fact, stated once so it is not lost later: none of the primary experiments cited on this site measured bone healing or cartilage repair as an outcome. What they measured was skin, gut lining, tendon, hair count and blood-vessel growth. This file reports what each study measured, in which species, and stops there.

The frame: bone, cartilage and the harder tissues

The hard tissues are the hard case, and that is precisely why they attract the most confident marketing.

Bone repairs through a vascular process — a fracture recruits blood supply and lays down a callus that is later remodelled. Articular cartilage does not. It is avascular, has no direct blood supply to recruit, and in adults has very little intrinsic capacity to repair itself. That asymmetry is standard orthopaedic teaching, and it sets the bar for any claim made in this category.

The best-documented mechanisms in the peptide literature are genuinely upstream of tissue repair. BPC-157 is pro-angiogenic through up-regulation and internalisation of the VEGFR2 receptor, with downstream Akt-eNOS signalling — shown in chick chorioallantoic membrane, rat hindlimb ischaemia and human endothelial cells ^[4]. Thymosin beta-4 sequesters monomeric actin in a 1:1 complex, capping both ends of the monomer, which is the structural basis for its effects on cell migration ^[12], and reviews connect that to angiogenesis and reduced scar formation across several models ^[10]. GHK-Cu stimulates fibroblast synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin ^[16].

Those are plausible inputs to a repair process. Plausibility is what gets sold. The cited experiments, however, stopped at soft tissue. The closest primary study to hard tissue in this whole collection is a fully transected rat Achilles tendon, where BPC 157 improved biomechanical, functional and microscopic recovery and improved collagen organisation ^[6] — dense connective tissue, at the bone interface, in a rat.

Two narrative reviews cover the wider musculoskeletal field and both land in the same place. A 2025 review of BPC-157 for musculoskeletal healing states that only three pilot studies have examined it in humans and that rigorous large-scale trials are lacking, and recommends treating it as investigational ^[2]. A 2026 sports-medicine review of approved and unapproved peptide therapies concludes that unapproved peptides including TB-500 and BPC-157 show favourable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that these compounds operate largely outside regulatory oversight ^[8].

So, stated without hedging: nothing collected here shows that any of these four peptides regrows or restores cartilage in a human being. No blinded human trial has tested that question for any of them.

Reading the species line

Every research claim on this site carries the model it came from, in the sentence that makes the claim rather than in a footnote. The distinction is substance, not a formality — a result in a Wistar rat and a result in a person are different kinds of object, and the whole commercial case for these compounds depends on readers treating them as the same kind.

The models represented in this collection are: Wistar rats ^[5][6][9], rats and beagle dogs ^[3], the chick chorioallantoic membrane and rat hindlimb ^[4], mice with chemically induced colitis and cultured human intestinal and immune cell lines ^[18], cultured human fibroblasts and gene-expression databases ^[14][16], ex vivo human skin ^[17], and living humans ^[1][11][15].

That last category is worth counting precisely, because it is small. The human primary data across all four compounds amounts to: an intravenous safety pilot of BPC-157 in two healthy adults at up to 20 mg, with no observed adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]; a randomised placebo-controlled Phase 1 study of intravenous full-length thymosin beta-4 in 40 healthy volunteers across four cohorts at 42, 140, 420 or 1260 mg, well tolerated with no dose-limiting toxicities ^[11]; a 6-month trial in 45 men with androgenetic alopecia of a combined 5-aminolevulinic acid and glycyl-histidyl-lysine formulation, which increased hair count by 52.6 and 71.5 versus 9.6 for placebo ^[15]; and an ex vivo study measuring how much copper crossed dermatomed human skin ^[17].

Two of those four were safety studies. One counted hairs. One measured skin permeability. None was an efficacy trial, and none had a musculoskeletal endpoint at all.

What a research peptide actually is

A peptide is a short chain of amino acids — the same chemistry as a protein, only smaller. The four covered here are synthesised rather than extracted, and each is sold by laboratory suppliers under a research-use-only label.

That label is not a formality either. None of these compounds is approved as a medicine by the FDA, the EMA, or any comparable regulator, for any indication. BPC-157 was placed by the FDA into a category of bulk drug substances identified as not eligible for pharmacy compounding under 503A pending further evaluation. TB-500 has no approved therapeutic indication and is encountered in veterinary and anti-doping contexts. GHK-Cu is a legal cosmetic ingredient in topical products in the US, EU and UK — under the name Copper Tripeptide-1 — while injectable or systemic use is unapproved and has no validated human pharmacokinetic basis. KLOW is a research-only co-formulation of four unapproved components.

Two further constraints follow. First, anti-doping: BPC-157 is prohibited at all times in sport by the World Anti-Doping Agency under its non-approved-substances category, and TB-500 and thymosin beta-4 fall under the prohibited peptide and growth-factor categories. Anti-doping laboratories have developed methods that detect TB-500 and its breakdown products. Second, supply: because these materials move through non-regulated channels, identity, purity and actual content are unverified outside formal studies. That uncertainty sits underneath every anecdote in circulation, because nobody reporting an outcome can say with confidence what was in the vial.